Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EMJP | ISIN: US52187K2006 | Ticker-Symbol: 5MC
Tradegate
19.04.24
18:14 Uhr
2,760 Euro
-0,240
-8,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LEAP THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LEAP THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,9003,04019:58
2,9003,04019:49

Aktuelle News zur LEAP THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.04.Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%6
11.04.Leap Therapeutics announces $40 million private placement 2
11.04.LEAP THERAPEUTICS, INC. - 8-K, Current Report2
18.03.Leap Therapeutics: Q4 Earnings Insights2
18.03.Leap Therapeutics files for $200M mixed shelf offering2
18.03.Leap Therapeutics Inc reports results for the quarter ended in December - Earnings Summary5
18.03.Leap Therapeutics GAAP EPS of -$0.46 beats by $0.103
18.03.LEAP THERAPEUTICS, INC. - 8-K, Current Report1
18.03.Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results115CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...
► Artikel lesen
18.03.LEAP THERAPEUTICS, INC. - 10-K, Annual Report-
23.01.LEAP THERAPEUTICS, INC. - 8-K, Current Report6
17.01.Leap Therapeutics rises as cancer therapy shows promise in mid-stage study9
16.01.LEAP THERAPEUTICS, INC. - 8-K, Current Report3
02.01.Leap Therapeutics, Inc.: Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients137CAMBRIDGE, Mass., Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
► Artikel lesen
12.12.23LEAP THERAPEUTICS, INC. - 8-K, Current Report1
24.11.23BKKT, LPTX and WGS among mid-day movers13
14.11.23Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know12
13.11.23Leap Therapeutics Inc reports results for the quarter ended in September - Earnings Summary4
13.11.23Recap: Leap Therapeutics Q3 Earnings2
13.11.23LEAP THERAPEUTICS, INC. - 8-K, Current Report1
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1